{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:21:34Z","timestamp":1788495694936,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SoLong"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Maintenance treatment with macrolide antibiotics has shown to be effective in reducing exacerbations in COPD patients. A major concern with prolonged treatment with antibiotics is the development of bacterial resistance. In this study we determined the effect of azithromycin on the development and acquisition of resistance to macrolides in the nasopharyngeal flora in COPD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study was part of the COLUMBUS trial, a randomised, double-blind, placebo-controlled trial to measure the effect of maintenance treatment with azithromycin in 92 COPD patients on the exacerbation rates during a 12-month period. In order to determine resistance to macrolides, we used a targeted metagenomic approach to measure the presence and relative abundance of specific macrolide resistance genes\n                      <jats:italic>ermB<\/jats:italic>\n                      ,\n                      <jats:italic>ermF<\/jats:italic>\n                      and\n                      <jats:italic>mefA<\/jats:italic>\n                      in throat samples collected at different time-points during this 12-month period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no increased risk for acquisition of macrolide resistance genes in the azithromycin group compared to the placebo group in COPD patients. However, loss of the macrolide resistance gene\n                      <jats:italic>ermB<\/jats:italic>\n                      was increased overtime in the placebo treated group compared to the azithromycin group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095 for the placebo group versus\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20090 for the azithromycin group at 12\u2009months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). The change in relative abundance of the three macrolide-resistance genes showed that all but one (\n                      <jats:italic>ermF<\/jats:italic>\n                      ) increased during treatment with azithromycin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The acquisition rate of macrolide resistance genes in COPD patients treated with azithromycin maintenance therapy was limited, but the relative abundance of macrolide resistance genes increased significantly over time compared to placebo.<\/jats:p>\n                    <jats:p>\n                      This study was part of the COLUMBUS trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00985244\">NCT00985244<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-020-00783-w","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T10:03:38Z","timestamp":1595930618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin"],"prefix":"10.1186","volume":"9","author":[{"given":"Remco S.","family":"Djamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-8839","authenticated-orcid":false,"given":"Sander","family":"Talman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eefje J. A.","family":"Schrauwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J. H.","family":"von Wintersdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra F.","family":"Wolffs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H. M.","family":"Savelkoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno M.","family":"van der Eerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A. J. W.","family":"Kluytmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","volume":"67","author":"S Suissa","year":"2012","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: Severe exacerbations and mortality. Thorax. 2012;67:957\u201363. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-201518.","journal-title":"Thorax"},{"key":"783_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1378\/chest.121.5.1449","volume":"121","author":"M Miravitlles","year":"2002","unstructured":"Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449\u201355. https:\/\/doi.org\/10.1378\/chest.121.5.1449.","journal-title":"Chest"},{"key":"783_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847\u201352. https:\/\/doi.org\/10.1136\/thorax.57.10.847.","journal-title":"Thorax"},{"key":"783_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s15010-008-7327-5","volume":"36","author":"G Rohde","year":"2008","unstructured":"Rohde G, Borg I, Wiethege A, et al. Inflammatory response in acute viral exacerbations of COPD. Infection. 2008;36:427\u201333. https:\/\/doi.org\/10.1007\/s15010-008-7327-5.","journal-title":"Infection"},{"key":"783_CR5","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1056\/NEJMra0800353","volume":"359","author":"S Sethi","year":"2008","unstructured":"Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355. https:\/\/doi.org\/10.1056\/NEJMra0800353.","journal-title":"N Engl J Med"},{"key":"783_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1183\/09031936.00208011","volume":"40","author":"M Yamaya","year":"2012","unstructured":"Yamaya M, Azuma A, Takizawa H, et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J. 2012;40:485\u201394. https:\/\/doi.org\/10.1183\/09031936.00208011.","journal-title":"Eur Respir J"},{"key":"783_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","volume":"178","author":"TAR Seemungal","year":"2008","unstructured":"Seemungal TAR, Wilkinson TMA, Hurst JR, et al. Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. Am J Respir Crit Care Med. 2008;178:1139\u201347. https:\/\/doi.org\/10.1164\/rccm.200801-145OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"783_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, et al. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011;365:689\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1104623.","journal-title":"N Engl J Med"},{"key":"783_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","volume":"2","author":"S Uzun","year":"2014","unstructured":"Uzun S, Djamin RS, Kluytmans JAJW, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361\u20138. https:\/\/doi.org\/10.1016\/S2213-2600(14)70019-0.","journal-title":"Lancet Respir Med"},{"key":"783_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","volume":"1","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013;1:262\u201374. https:\/\/doi.org\/10.1016\/S2213-2600(13)70038-9.","journal-title":"Lancet Respir Med"},{"key":"783_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/AAC.02067-13","volume":"58","author":"H Li","year":"2014","unstructured":"Li H, Liu DH, Chen LL, et al. Meta-Analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother. 2014;58:511\u20137. https:\/\/doi.org\/10.1128\/AAC.02067-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"783_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejmech.2018.04.059","volume":"152","author":"SL Badshah","year":"2018","unstructured":"Badshah SL, Ullah A. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV. Eur J Med Chem. 2018;152:393\u2013400. https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.059.","journal-title":"Eur J Med Chem"},{"key":"783_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1517\/14656566.2013.763030","volume":"14","author":"JP Lynch","year":"2013","unstructured":"Lynch JP, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum \u03b2-lactamases and carbapenemases). Expert Opin Pharmacother. 2013;14:199\u2013210. https:\/\/doi.org\/10.1517\/14656566.2013.763030.","journal-title":"Expert Opin Pharmacother"},{"key":"783_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/IDR.S173867","volume":"11","author":"B Aslam","year":"2018","unstructured":"Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645\u201358. https:\/\/doi.org\/10.2147\/IDR.S173867.","journal-title":"Infect Drug Resist"},{"key":"783_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dks373","volume":"68","author":"KL Blake","year":"2013","unstructured":"Blake KL, O\u2019Neill AJ. Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J Antimicrob Chemother. 2013;68:12\u20136. https:\/\/doi.org\/10.1093\/jac\/dks373.","journal-title":"J Antimicrob Chemother"},{"key":"783_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1128\/AAC.00906-09","volume":"54","author":"A Liu","year":"2010","unstructured":"Liu A, Tran L, Becket E, et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: Generating an antibiotic bar code. Antimicrob Agents Chemother. 2010;54:1393\u2013403. https:\/\/doi.org\/10.1128\/AAC.00906-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"783_CR17","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1128\/AAC.00580-10","volume":"54","author":"JL Floyd","year":"2010","unstructured":"Floyd JL, Smith KP, Kumar SH, et al. LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5406\u201312. https:\/\/doi.org\/10.1128\/AAC.00580-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"783_CR18","doi-asserted-by":"publisher","unstructured":"Hu RM, Liao ST, Huang CC, et al. An Inducible Fusaric Acid Tripartite Efflux Pump Contributes to the Fusaric Acid Resistance in Stenotrophomonas maltophilia. PLoS One. 2012;7. https:\/\/doi.org\/10.1371\/journal.pone.0051053.","DOI":"10.1371\/journal.pone.0051053"},{"key":"783_CR19","doi-asserted-by":"publisher","unstructured":"Kim C, Mwangi M, Chung M, et al. The mechanism of heterogeneous beta-lactam resistance in MRSA: Key role of the stringent stress response. PLoS One. 2013;8. https:\/\/doi.org\/10.1371\/journal.pone.0082814.","DOI":"10.1371\/journal.pone.0082814"},{"key":"783_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.gene.2012.02.008","volume":"498","author":"W Ogawa","year":"2012","unstructured":"Ogawa W, Onishi M, Ni R, et al. Functional study of the novel multidrug efflux pump KexD from Klebsiella pneumoniae. Gene. 2012;498:177\u201382. https:\/\/doi.org\/10.1016\/j.gene.2012.02.008.","journal-title":"Gene"},{"key":"783_CR21","doi-asserted-by":"publisher","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","volume":"6","author":"DC Hooper","year":"2016","unstructured":"Hooper DC, Jacoby GA. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med. 2016;6:a025320. https:\/\/doi.org\/10.1101\/cshperspect.a025320.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"783_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","volume":"369","author":"S Malhotra-Kumar","year":"2007","unstructured":"Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(07)60235-9.","journal-title":"Lancet"},{"key":"783_CR23","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1056\/NEJMc1111248","volume":"365","author":"D H","year":"2011","unstructured":"D H. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011;365:2234\u20137. https:\/\/doi.org\/10.1056\/NEJMc1111248.","journal-title":"N Engl J Med"},{"key":"783_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/AAC.35.7.1267","volume":"35","author":"R Leclercq","year":"1991","unstructured":"Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother. 1991;35:1267\u201372. https:\/\/doi.org\/10.1128\/AAC.35.7.1267.","journal-title":"Antimicrob Agents Chemother"},{"key":"783_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-2958.1996.01521.x","volume":"22","author":"J Clancy","year":"1996","unstructured":"Clancy J, Petitpas J, Dib\u2010Hajj F, et al. Molecular cloning and functional analysis of a novel macrolide\u2010resistance determinant, mefA , from Streptococcus pyogenes. Mol Microbiol. 1996;22:867\u201379. https:\/\/doi.org\/10.1046\/j.1365-2958.1996.01521.x.","journal-title":"Mol Microbiol"},{"key":"783_CR26","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1128\/aac.41.10.2251","volume":"41","author":"A Tait-Kamradt","year":"1997","unstructured":"Tait-Kamradt A, Clancy J, Cronan M, et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:2251\u20135. https:\/\/doi.org\/10.1128\/aac.41.10.2251.","journal-title":"Antimicrob Agents Chemother"},{"key":"783_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3201\/eid2004.131718","volume":"20","author":"CJH von Wintersdorff","year":"2014","unstructured":"von Wintersdorff CJH, Penders J, Stobberingh EE, et al. High rates of antimicrobial drug resistance gene acquisition after international travel, the Netherlands. Emerg Infect Dis. 2014;20:649\u201357. https:\/\/doi.org\/10.3201\/eid2004.131718.","journal-title":"Emerg Infect Dis"},{"key":"783_CR28","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1099\/mic.0.028233-0","volume":"155","author":"R Szczepanowski","year":"2009","unstructured":"Szczepanowski R, Linke B, Krahn I, et al. Detection of 140 clinically relevant antibiotic-resistance genes in the plasmid metagenome of wastewater treatment plant bacteria showing reduced susceptibility to selected antibiotics. Microbiology. 2009;155:2306\u201319. https:\/\/doi.org\/10.1099\/mic.0.028233-0.","journal-title":"Microbiology"},{"key":"783_CR29","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1128\/AEM.02799-06","volume":"73","author":"J Chen","year":"2007","unstructured":"Chen J, Yu Z, Michel FC, et al. Development and application of real-time PCR assays for quantification of erm genes conferring resistance to macrolides-lincosamides-streptogramin B in livestock manure and manure management systems. Appl Environ Microbiol. 2007;73:4407\u201316. https:\/\/doi.org\/10.1128\/AEM.02799-06.","journal-title":"Appl Environ Microbiol"},{"key":"783_CR30","doi-asserted-by":"publisher","unstructured":"Klindworth A, Pruesse E, Schweer T, et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencingbased diversity studies. Nucleic Acids Res. 2013;41. https:\/\/doi.org\/10.1093\/nar\/gks808.","DOI":"10.1093\/nar\/gks808"},{"key":"783_CR31","doi-asserted-by":"publisher","first-page":"45e","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:45e\u201345. https:\/\/doi.org\/10.1093\/nar\/29.9.e45.","journal-title":"Nucleic Acids Res"},{"key":"783_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1086\/324626","volume":"34","author":"R Leclercq","year":"2002","unstructured":"Leclercq R. Mechanisms of Resistance to Macrolides and Lincosamides: Nature of the Resistance Elements and Their Clinical Implications. Clin Infect Dis. 2002;34:482\u201392. https:\/\/doi.org\/10.1086\/324626.","journal-title":"Clin Infect Dis"},{"key":"783_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1128\/AAC.00781-08","volume":"53","author":"PE Varaldo","year":"2009","unstructured":"Varaldo PE, Montanari MP, Giovanetti E. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother. 2009;53:343\u201353. https:\/\/doi.org\/10.1128\/AAC.00781-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"783_CR34","doi-asserted-by":"publisher","first-page":"6898","DOI":"10.1128\/JB.183.23.6898-6907.2001","volume":"183","author":"G Garza-Ramos","year":"2001","unstructured":"Garza-Ramos G, Xiong L, Zhong P, et al. Binding site of macrolide antibiotics on the ribosome: New resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001;183:6898\u2013907. https:\/\/doi.org\/10.1128\/JB.183.23.6898-6907.2001.","journal-title":"J Bacteriol"},{"key":"783_CR35","unstructured":"Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD. 2020;89. https:\/\/goldcopd.org\/. Accessed 14 Jan 2020."}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00783-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-020-00783-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00783-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T19:06:59Z","timestamp":1627412819000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00783-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00783-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-28234\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-28234\/v2","asserted-by":"object"}]},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The independent Ethics Committee \u201cToetsingscommissie Wetenschappelijk Onderzoek Rotterdam\u201d (TWOR) granted approval for his study (NL29500.101.09). All patients agreed and signed an informed consent before entering this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}